Please login to the form below
key opinion leaders
This page shows the latest key opinion leaders news and features for those working in and with pharma, biotech and healthcare.
Biogen defends aducanumab filing plan amid scepticism
Usual’ is the key word in the last sentence however, as Biogen and others think that mixed data may be enough for a green light from the FDA given the desperate ... GlobalData analyst Alessio Brunello said today that key opinion leaders (KOLs) polled
Latest news
-
ACPs to lead gene therapies in haemophilia market growth
GlobalData found that key opinion leaders in the eight major markets (the US, France, Germany, Italy, Spain, UK, Japan, and China) are highly optimistic about these therapies and agree that they
-
GSK to reverse ‘no KOLs’ policy, admitting it has hit marketing
Company seeking to revive lacklustre marketing performance. GlaxoSmithKline is to reverse its ban on paying healthcare professionals and key opinion leaders (KOLs), admitting that the policy has hit awareness of its ... Nevertheless, GSK will be keen to
-
A unique ecosystem
How life science and healthcare clusters are driving innovation. Innovation is a key driver for economic growth in the 21st century. ... Start-ups from either cluster could attend B2B meetings and presentations by key opinion leaders with the objective
-
Harnessing the unrivalled power of key opinion leaders
Engaging early. Engaging the right key opinion leaders (KOLs) at an early stage in the life cycle, and utilising their expertise and influence, is key to securing timely and positive data ... Also, working with KOLs in each of your target markets is key
-
Spink wins gastroenterology society account
ESPGHAN’s annual congress is attended by over 4, 000 delegates and globally attracts key opinion leaders in the field of paediatric gastroenterology, hepatology and nutrition. ... Managing relations with the medical trade and global press, Spink will
More from news
Approximately 0 fully matching, plus 93 partially matching documents found.
Latest Intelligence
-
The ‘blueprint’ for MSL success is changing
MSLs are active in the pre-launch phase, promoting disease awareness and engagement with Key Opinion Leaders. ... Key performance indicators are aligned to the framework, and competencies help to consistently deliver vital components of the SMOs.
-
The power of high-value, highly relevant content to support clinical decisions
The year- long digital campaign included a range of materials – including educational articles, quizzes, emails and banners – featuring relevant Key Opinion Leaders. ... The gap is made credible because it is based on real HCP engagement –
-
Breaking free
Similarly, identity can be key; if a new behaviour leads to a more positive self-image, behaviour is again reinforced over time. ... Digital interactions – through personalised, targeted content – can help. We’ve seen numerous examples of this,
-
Breaking from tradition - social media at medical congresses
Consider the role of partners, whether Digital Opinion Leaders (those HCPs who are actively influencing the conversation within a therapy area), research organisations, advocacy groups or, where appropriate, expert patients, for ... 4. Provide a platform
-
Immunotherapy combination trials Q&A
In order to ensure efficient spend and effort, these key criteria should be met positively and, most importantly, only those sites that have the capabilities to deliver IO trials, as well ... Patient referral networks, recruitment materials and scientific
More from intelligence
Approximately 3 fully matching, plus 34 partially matching documents found.
Latest appointments
-
Ashfield appoints new UK head of patient solutions
She has also worked with many key opinion leaders (KOLs) and facilitated advisory boards to aid the delivery of new models of patient care pathways, and was the winner of the
-
Bone Therapeutics strengthens clinical development team
In addition to his specific experience with cell therapy products, Dr Forte has extensive experience in interacting with regulatory bodies and establishing strong relationships with investigators and key opinion leaders.”.
-
Biomunex appoints scientific and strategic advisors
Dr Pierre-Emmanuel Gerard, chief executive officer at Biomunex, said: “We are very pleased to welcome Dr Amigorena and Dr Grabulovski as key advisors. ... As international key opinion leaders they will play an instrumental role as we advance our first
-
ABPI appoints Pfizer’s Colette Goldrick as first Northern Ireland director
Will develop relationships with key opinion leaders in region. T he Association of the British Pharmaceutical Industry (ABPI) has appointed Pfizer Europe's f ormer head of head of public affairs ... A native of Northern Ireland, Goldrick will be tasked
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
INFOSHEET 02: Improving diversity in your patient recruitment strategy
If your study needs to reach an established patient group, or a minority population, then you’ve got to engage community leaders, patient advocates, and key opinion leaders throughout the development
-
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Create authentic relationships with their key opinion leaders. To learn more about the methodology used and the results of this client’s Longitudinal Expert Engagement Plan (LEEP), download the full customer
-
Diagnosing MS: are we getting it right?
This is even more important when some key opinion leaders within neurology advocate the need to treat early with efficacious drugs for the best chance to delay progression. ... This is a key diagnostic tool in MS, without which an official diagnosis is
-
Good data is nothing without advocacy
These respected key opinion leaders (KOLs) have a strong voice and can provide invaluable advice to HCPs at meetings and congresses, including giving feedback via advisory boards. ... Recognition and relationships:. Brand/company recognition. Overall
-
How can pharma engage with key stakeholders on NHS service transformation?
Industry should also refine its proposition for transformation leads, medicines management staff and other key opinion leaders (KOLs), who may have different drivers and priorities. . ... Pharma can also take a lead in facilitating discussions between
More from PMHub
Approximately 0 fully matching, plus 21 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- Lilly’s Verzenio scores a win in early-stage breast cancer
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
- Q&A: Isabel Gibson
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
